← Back to Search

Neuromodulation

Neuromodulation for Schizophrenia

N/A
Waitlist Available
Research Sponsored by Scion NeuroStim
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks from baseline to end of treatment
Awards & highlights

Study Summary

This trial will evaluate a new way to treat schizophrenia by stimulating the brain and using imaging to measure the effects.

Who is the study for?
This trial is for adults over 18 with schizophrenia or schizoaffective disorder, who have trouble recognizing their illness. They must speak English, be on stable medication for two months, and able to consent. Excluded are those with recent eye surgery, ear infections, substance dependence (except caffeine/nicotine), metal implants/pacemakers affecting MRI scans, pregnancy, vestibular dysfunction, severe medical conditions or thought disorders.Check my eligibility
What is being tested?
The study tests a non-invasive brainstem modulation device's effect on illness awareness in schizophrenia patients. It involves safe brain stimulation alongside neuroimaging to track changes in the brain related to treatment response and recognition of the illness.See study design
What are the potential side effects?
While specific side effects aren't listed here as it's investigational and non-invasive stimulation is generally considered safe; potential risks may include discomfort at the stimulation site or temporary hearing issues due to proximity to the ear.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks from baseline to end of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks from baseline to end of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Illness Awareness
Secondary outcome measures
Examine changes in brain network activity

Trial Design

3Treatment groups
Experimental Treatment
Group I: Investigational Stimulation Pattern-Open LabelExperimental Treatment1 Intervention
Group II: Investigational Stimulation Pattern 2-RandomizedExperimental Treatment1 Intervention
Group III: Investigational Stimulation Pattern 1-RandomizedExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthOTHER
355 Previous Clinical Trials
81,210 Total Patients Enrolled
58 Trials studying Schizophrenia
4,197 Patients Enrolled for Schizophrenia
Scion NeuroStimLead Sponsor
13 Previous Clinical Trials
696 Total Patients Enrolled
1 Trials studying Schizophrenia
34 Patients Enrolled for Schizophrenia

Media Library

Non-invasive brainstem modulation device (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT05580211 — N/A
Schizophrenia Research Study Groups: Investigational Stimulation Pattern 1-Randomized, Investigational Stimulation Pattern 2-Randomized, Investigational Stimulation Pattern-Open Label
Schizophrenia Clinical Trial 2023: Non-invasive brainstem modulation device Highlights & Side Effects. Trial Name: NCT05580211 — N/A
Non-invasive brainstem modulation device (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05580211 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are more participants required for this experiment?

"The information available on clinicaltrials.gov states that recruitment for this trial has ended, after beginning October 15th 2022 and being updated most recently October 13th 2022. Nonetheless, there are over 300 other trials actively searching for participants right now."

Answered by AI

Who else is applying?

What state do they live in?
California
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
3+

How responsive is this trial?

Typically responds via
Email
Recent research and studies
clinicaltrials.govStudy
Neuromodulation for Schizophrenia
2022. "Neuromodulation for Schizophrenia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05580211.
All > Schizophrenia
~17 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top